Valneva SE
Close on Oct 19, 2026
About Valneva
Biological Products, (No Diagnostic Substances), SIC 2836
Valneva SE is a specialty vaccine company that discovers, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with significant unmet medical needs. The company's commercialized product portfolio features travel vaccines, including IXIARO for the prevention of Japanese encephalitis, DUKORAL for cholera and traveler's diarrhea caused by LT-ETEC, and IXCHIQ for chikungunya. Valneva serves travelers, military personnel, and global populations vulnerable to endemic infectious threats. Additionally, it advances late-stage clinical candidates, such as a Lyme disease vaccine developed in partnership with Pfizer and a tetravalent Shigella vaccine candidate.
The company operates manufacturing and research facilities across Europe, including production sites in Scotland and Sweden. It conducts business and maintains wholly owned operating subsidiaries in France, Austria, Scotland, Sweden, England and Wales, Canada, and the United States. Valneva maintains its registered corporate headquarters in Lyon, France.
Summary of the business section of Valneva's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Valneva SE
- Founded
- 1999
- Headquarters
- Saint-Herblain, I0
- Address
- 6, Rue Alain Bombard 44800
- Phone
- 33 2 28 07 37 10
- Website
- valneva.com
- Employees
- 140, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- I0
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Associes, Paris, France
Stock & identifiers
- Ticker
- VALN
- Exchange
- Nasdaq
- IPO date
- May 7, 2021
- Shares outstanding
- 174M, Dec 31, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1836564
- CUSIP
- 92025Y103
- ISIN
- US92025Y1038
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Valneva's leadership is listed in its proxy statement (Form DEF 14A).
Employees
Headcount reported in annual reports
“The site supports multi‑product manufacturing and serves as our viral vaccine center of excellence, employing approximately 140 staff.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 7, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| May 3, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |